The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study. Methods: The 4EVER trial invest...

Full description

Bibliographic Details
Main Authors: Peyman Hadji, Oliver Stoetzer, Thomas Decker, Christian M. Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, Andrea Distelrath, Peter A. Fasching, Michael P. Lux, Diana Lüftner, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Eva-Marie Grischke, Hans Tesch
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:Journal of Bone Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137418301131

Internet

http://www.sciencedirect.com/science/article/pii/S2212137418301131

Similar Items